Rituximab-containing therapy for chronic lymphocytic leukaemia Reply

被引：0

作者：

Hallek, M. ^{[1
]}

Fink, A. ^{[1
]}

Busch, R. ^{[2
]}

Fischer, K. ^{[1
]}

机构：

[1] Univ Cologne, Dept Internal Med 1, Ctr Integrated Oncol, D-50924 Cologne, Germany

[2] Tech Univ Munich, Inst Med Stat & Epidemiol, Munich, Germany

来源：

LANCET | 2011年 / 377卷 / 9761期

关键词：

GUIDELINES; DIAGNOSIS;

D O I：

10.1016/S0140-6736(11)60043-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：206 / 206

页数：1

相关论文

共 3 条

[1] National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
Cheson, BD
Bennett, JM
Grever, M
Kay, N
Keating, MJ
OBrien, S
Rai, KR
[J]. BLOOD, 1996, 87 (12) : 4990 - 4997
[2] Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaernia during fludarabine-based first line therapy
Eichhorst, Barbara F.
Busch, Raymonde
Schweighofer, Carmen
Wendtner, Clemens M.
Emmerich, Berthold
Hallek, Michael
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (01) : 63 - 72
[3] Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Hallek, Michael
Cheson, Bruce D.
Catovsky, Daniel
Caligaris-Cappio, Federico
Dighiero, Guillaume
Doehner, Hartmut
Hillmen, Peter
Keating, Michael J.
Montserrat, Emili
Rai, Kanti R.
Kipps, Thomas J.
[J]. BLOOD, 2008, 111 (12) : 5446 - 5456